1月8日 - ** 虚拟慢性病治疗提供商Omada Health OMDA.O股价盘前上涨2%至16.90美元
** 该公司称，其项目中的成员服用GLP-1药物后体重减轻了18.4% (link)，而其他研究的结果为11.9%。
** 公司称，所有参与者的平均体重减轻了 16.3%，几乎是同类研究的两倍
** 67% 的人坚持服药一年，而其他研究中只有 47% 至 49%，OMDA 补充道
** 公司称，该计划将诺和诺德公司的semaglutide和礼来公司的tirzepatide等药物与指导和生活方式建议相结合
** 截至上次收盘，该公司股价在过去一年中上涨了 ~5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.